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Abstract
Purpose This study assessed the diagnostic accuracy of C-
reactive protein (CRP) after gastroesophageal cancer resec-
tion for postoperative inflammatory complications (PIC).
Methods The clinical data and CRP values of patients oper-
ated on for gastroesophageal cancer surgery between 1997
and 2009 were retrospectively analyzed. The results of this
study were compared with published data using a meta-
analytic approach for diagnostic outcomes.
Results Of 210 patients included in the study, 59 developed
PIC (28.1 %; 95 % CI: 22.5–34.5 %). On the postoperative
day (POD) 4 and 7, CRP had the best diagnostic accuracy
for PIC (AUC 0.77; 95 % CI, 0.64–0.91, AUC 0.81; 95 %
CI, 0.71–0.91). Using a cut-off value of 141 mg/L (95 % CI,
131–278 mg/L) for CRP on POD 4, the sensitivity was 0.78
(95 % CI, 0.55–0.91), the specificity was 0.70 (95 % CI,
0.53–0.83) and the NPV was 0.89 (95 % CI, 0.77–0.95). The
in-hospital mortality rate was 3.3 % (95%CI, 1.5–6.9 %). In a
diagnostic meta-analysis that included two additional studies,
CRP had a significant predictive value after POD 3.
Conclusion There is limited evidence for the diagnostic
accuracy of CRP levels for PIC after gastroesophageal can-
cer surgery. CRP levels on POD 4 might be useful to rule
out PIC, but its diagnostic accuracy is moderate at best. For
clinical routine use CRP levels are clearly not sufficient to
predict PIC and have to be interpreted in the context of the
whole clinical picture.
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Introduction
Fast track surgery is slowly gaining acceptance into clinical
practice; however, there are still concerns about the safety,
in particular about postoperative complications after the
early discharge of the patients. Especially for operations
with a high postoperative complication rate, like gastro-
esophageal cancer surgery, this is still an issue despite a
recent study with excellent results after fast-track surgery of
gastric cancer [1]. Reports about morbidity and mortality
after gastroesophageal cancer surgery vary significantly in
the literature, with particularly higher complication rates
after esophagectomy [2–4].
A laboratory value predicting, or in the case of fast track
surgery reliably excluding, postoperative inflammatory com-
plications (PIC) would be extremely helpful. Furthermore,
even for patients with conventional perioperative manage-
ment, early diagnosis of PIC would allow timely therapy of
potentially septic patients and thus would improve their sur-
vival [5–8]. C-reactive protein (CRP), a widely used labora-
tory value for an acute inflammatory response [9], would be a
potential candidate for such a marker. Several studies indicat-
ed that CRP can be used to predict postoperative inflammatory
complications [10–12]. However, some of these studies suffer
from small study sizes and lack an adequate reporting of
diagnostic results.
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Thus, the aim of this retrospective study was to analyze
the diagnostic accuracy of CRP to detect PIC after gastro-
esophageal cancer surgery in an unselected patient cohort.
In addition, we pooled our data with published data for a
meta-analysis of diagnostic outcome data.
Patients and methods
For this retrospective study, all patients operated on for gas-
troesophageal cancer resection between January 1997 and
December 2009 were identified from the institutional data-
base. All patients routinely received preoperative antibiotic
prophylaxis (500 mg metronidazole i.v. and 2000 mg cefa-
mandole i.v. 60 min before the surgery) and anticoagulation
with a lowmolecular weight heparin, according to the hospital
guidelines. Some of the patients received selective digestive
tract decontamination (SDD) [13, 14]: a solution of polymyx-
in (100 mg), tobramycin (80 mg), vancomycin (125 mg), and
nystatin (500 mg) was administered orally four times a day
from the morning of the day before surgery to the seventh
postoperative day. Between postoperative day 5 (POD 5) and
POD 7, radiological exams were routinely performed with an
orally administered water-soluble contrast agent.
Data collection and definitions
The data were gathered retrospectively from the medical
records. Mortality was defined as any death occurring during
postoperative hospitalization. Anastomotic leakage was de-
fined as an extravasation of the endoluminally administered
water-soluble contrast agent on radiography or computed
tomography or if proven during reoperation. Wound infec-
tions and intra-abdominal abscesses that were not related to
anastomotic leakages, according to the diagnosis from the
medical records or the operation protocols, were recorded.
The presence of pneumonia was recorded when it was men-
tioned explicitly as a diagnosis in the medical records or as a
radiological finding. Urinary infections, central line infec-
tions, Clostridium difficile colitides, and any other forms of
infections were recorded when explicitly mentioned in the
medical file, independent of the treatment. Postoperative mor-
bidity was rated according to the classification by Dindo et al.
[15]. Neoadjuvant therapy was performed according to the
decision of the interdisciplinary tumor board. Tumors of the
gastroesophageal junction were classified according to Sie-
wert [16]. Type I and II tumors were considered as esophageal
cancers and type III tumors as gastric cancers.
CRP measurement
The CRP concentrations were measured with an automated
analytical system (Unicel DxC 800, Beckman Coulter, reference
range <8 mg/L). Until August 2005, the measuring range was
3 to 300 mg/L, afterwards, the range was 1 to 500 mg/L.
Therefore, CRP values exceeding 300 mg/L were reduced to
300 mg/L, and values under 3 mg/L were set to 3 mg/L.
Meta-analysis
The authors searched the National Library of Medicine
(Medline) and Cochrane Library databases in March 2011
for any studies that assessed the diagnostic accuracy of CRP
for any PIC following gastroesophageal cancer surgery. The
reference lists of each study were searched for additional
publications. Data analysis established the number of patients
with and without infectious complications and the number of
patients who exceeded a distinct cut-off value, which resulted
in a two-by-two-table for test outcome and clinical outcome.
These data were not provided explicitly in the included
studies and were therefore estimated from sensitivity and
specificity.
Statistical analysis and authorization
The statistical analysis was performed using R (http://www.
r-project.org). Two-sided p values of less than 0.05 were
considered to be statistically significant. Continuous data
are expressed as the mean±standard deviation or median
and interquartile range (IQR), as indicated. The chi-square
test was used to compare proportions, and the Mann–Whit-
ney test was used to compare continuous data. Generalized
estimation equation models were applied for multivariate
analysis of CRP levels (mean ranks) with stratification for
PIC. The diagnostic accuracy was determined by the area
under the curve (AUC) of the receiver operating character-
istic (ROC) curve [17]. The AUCs were computed using the
nonparametric trapezoidal method and their 0.95 confidence
limits (95 % CI), according to DeLong et al. [18]. The
optimal cut-off values were determined by maximizing the
Youden's index (0sensitivity+specificity−1). Nonparametric
95 % CIs for the cut-off values were computed with boot-
strapping using the percentile method (5,000 estimates) [19].
Multivariate ROC analysis was performed with binormal
ROC-generalized linear regression models with tie correction
[20].
Meta-analyses of sensitivity and specificity were performed
using the random effects model of DerSimonian and Laird
[21]. Cochran's Q statistic was applied for the analysis of
statistical heterogeneity. For each study, a diagnostic odds ratio
(DOR) was calculated. The DOR is the ratio of the odds of a
positive result in a patient with PIC compared to a patient
without PIC: (sensitivity/(1−sensitivity))/((1−specificity)/
specificity). It is a measure of the overall diagnostic accuracy
and is less affected by the selected threshold and the prevalence
than specificity or sensitivity alone [22].
728 Langenbecks Arch Surg (2012) 397:727–736
The study was approved by the Swiss Federal Expert
Commission for Physician Confidentiality and the state ethics
review board. It was registered under www.clinicaltrials.gov/
ct2/show/NCT01249534.
Results
Exclusion criteria, baseline, and outcome
A total of 221 patients operated on for gastroesophageal
cancer with a clinical follow-up of at least 30 days were
identified from the database. Eleven patients were excluded
Table 1 Distribution of
inflammatory complica-
tions (N0210)
aCholecystitis, pancrea-
titis, urogenital, and
cerebral infections
Any inflammatory
complication
59 (28.1 %)
Including:
Anastomotic leakage 14 (6.7 %)
Deep abscess 9 (4.3 %)
Wound infection 5 (2.4 %)
Pneumonia 13 (6.2 %)
Urinary tract infection 5 (2.4 %)
Central line infection 11 (5.2 %)
Clostridium difficile
colitis
4 (1.9 %)
Other infectiona 10 (4.8 %)
Table 2 Baseline characteristics, main operation type, and clinical outcomes
Total Inflammatory complications p
N0210 Yes (N059) No (N0151)
Age (years) 63.3±12.2 63.6±12.9 63.2±12.0 0.505a
Body mass index (kg/m2) 24.6±4.3 25.0±4.1 24.4±4.4 0.327a
Gender Male 135 (64.3 %) 40 (67.8 %) 95 (62.9 %) 0.507b
Female 75 (35.7 %) 19 (32.2 %) 56 (37.1 %)
ASA stage I 8 (3.8 %) 4 (6.8 %) 4 (2.6 %) 0.742a, c
II 132 (62.9 %) 33 (55.9 %) 99 (65.6 %)
III 65 (31.0 %) 21 (35.6 %) 44 (29.1 %)
IV 1 (0.5 %) 0 (0.0 %) 1 (0.7 %)
Missing data 4 (1.9 %) 1 (1.7 %) 3 (2.0 %)
Tumor site Gastric 152 (72.4 %) 38 (64.4 %) 114 (75.5 %) 0.106b
Esophageal 58 (27.6 %) 21 (35.6 %) 37 (24.5 %)
Neoadjuvant therapy N (%) 72 (34.3 %) 16 (27.1 %) 56 (37.1 %) 0.171b
Selective decontamination
of the digestive tract
N (%) 177 (84.3 %) 39 (66.1 %) 138 (91.4 %) <0.001b
Main operation Total gastrectomy 98 (46.7 %) 26 (44.1 %) 72 (47.7 %) 0.934b
Transhiatal extended gastrectomy 49 (23.3 %) 13 (22.0 %) 36 (23.8 %)
Subtotal gastrectomy 21 (10.0 %) 6 (10.2 %) 15 (9.9 %)
Merendino procedure 15 (7.1 %) 6 (10.2 %) 9 (6.0 %)
Transmediastinal esophagectomy 11 (5.2 %) 3 (5.1 %) 8 (5.3 %)
Transthoracic esophagectomy 16 (7.6 %) 5 (8.5 %) 11 (7.3 %)
Dindo classification of
postoperative complications
Grade I 4 (1.9 %) 0 (0.0 %) 4 (2.6 %) <0.001a
Grade II 153 (72.9 %) 25 (42.4 %) 128 (84.8 %)
Grade IIIa 13 (6.2 %) 7 (11.9 %) 6 (4.0 %)
Grade IIIb 20 (9.5 %) 13 (22.0 %) 7 (4.6 %)
Grade IVa 12 (5.7 %) 8 (13.6 %) 4 (2.6 %)
Grade IVb 1 (0.5 %) 1 (1.7 %) 0 (0.0 %)
Grade V 6 (2.9 %) 5 (8.5 %) 1 (0.7 %)
Hospitalization (days) 27.5±15.3 37.9±21.1 23.4±9.8 <0.001a
Mortality N (%) 7 (3.3 %) 5 (8.5 %) 2 (1.3 %) 0.009b
aMann–Whitney test
b Chi-square test
c Analysis without missing data
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because no CRP values were available. Thus, 210 patients
were included in the study.
Inflammatory complications occurred in 59 of the 210
patients (28.1 %; 95 % CI, 22.5–34.5 %). An anastomotic
leakage occurred in fourteen patients (6.7 %; 95 % CI, 3.9–
11.0 %), diagnosed at a median of 7.0 days post-surgery
(IQR, 4.0–11.3 days). Thirteen patients developed pneumo-
nia (6.2 %; 95 % CI, 3.6–10.4 %). The distribution of the
inflammatory complications is summarized in Table 1. Seven
patients died during hospitalization (in-hospital mortality,
3.3 %, 95 % CI, 1.5–6.9 %).
Table 2 compares the baseline, treatment, and outcome
data of the patients with and without inflammatory compli-
cations. The patients with inflammatory complications re-
ceived selective digestive tract decontamination less often
and had a significantly longer hospital stay and a signifi-
cantly increased postoperative morbidity and mortality. As a
tendency, inflammatory complications occurred more often
in patients with esophageal cancer.
Postoperative course of CRP levels
On average, 2.5 CRP values were available for each patient
until POD 10. Table 3 lists the median CRP levels of patients
with and without inflammatory complications. Patients with-
out inflammatory complications had the highest CRP values
on POD 2 and values decreased thereafter continuously until
POD 8. Patients with inflammatory complications reached
their peak CRP values one day later (POD 3) but also had a
continuous decrease afterwards until POD 8. From POD 3 to
POD 10, CRP values of patients with inflammatory compli-
cations were clearly higher than the values from patients
without inflammatory complications. This difference was
statistically significant for all days except for POD 3 and 5
(p00.064 and p00.065). Multivariate analysis of the CRP
level of patients with PIC showed that tumor site (p00.541),
neoadjuvant therapy (p00.450) and SDD (p00.097, tendency
for lower CRP levels) have no significant influence. Similarly,
for patients without PIC, neoadjuvant therapy (p00.121) and
SDD (p00.106) had no statistically significant influence,
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Fig. 1 Empirical ROC plots for the diagnostic accuracy of the CRP
level for the detection of inflammatory complications. For the postop-
erative days 4–7, the sensitivity was plotted over the false positive rate
(1−specificity). The greater the area under the curve (AUC), the better
the diagnostic accuracy. A marker without predictive value (results by
pure chance) would follow the diagonal (gray dotted line) and thus
would have an AUC of 0.5. A perfect marker (sensitivity01 and
specificity01 for at least one cut-off value) would have an AUC of 1
Table 3 Postoperative course
of the CRP levels
aMann–Whitney test
bMedian (range)
Total Inflammatory complications pa
Yes No
N Med (IQR) N Med (IQR) N Med (IQR)
CRP (mg/L)
Preoperatively 31 4 (3–13) 8 5 (3–9) 23 4 (2–18) 0.650
POD 1 11 85 (78–133) 2 95 (84–105)b 9 85 (75–152) 0.906
POD 2 42 153 (99–215) 11 141 (74–190) 31 171 (100–215) 0.520
POD 3 57 179 (134–247) 19 240 (156–267) 38 167 (127–228) 0.064
POD 4 51 136 (87–248) 18 221 (139–285) 33 107 (76–157) 0.001
POD 5 51 98 (59–209) 17 177 (79–244) 34 91 (57–171) 0.065
POD 6 58 91 (57–150) 18 154 (79–225) 40 82 (53–116) 0.017
POD 7 71 91 (35–162) 25 162 (91–248) 46 61 (31–121) <0.001
POD 8 55 60 (22–142) 21 104 (42–235) 34 45 (18–113) 0.043
POD 9 53 121 (30–174) 22 148 (109–192) 31 64 (19–153) 0.004
POD 10 48 76 (40–130) 17 96 (74–184) 31 66 (22–97) 0.036
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although there was a tendency to lower CRP levels. However,
the tumor site had a significant influence (p00.002), with
increased CRP levels for esophageal cancer.
Diagnostic accuracy of CRP
Based on the area under the ROC curve, CRP had the best
diagnostic accuracy on POD 7 (AUC 0.81, 95 % CI, 0.71–
0.91) followed by POD 4 (AUC 0.77, 95 % CI, 0.64–0.91)
(Fig. 1). The diagnostic outcome data of CRP for PIC are
summarized in Table 4. The statistically optimal cut-off
value for the CRP level on POD 4 was 141 mg/L, based
on data from 51 patients. For this cut-off, the sensitivity is
78 % (14 of 18 patients with complications had a CRP value
above the cut-off) and the specificity is 70 % (23 of 33
patients without complications had a CRP value below the
cut-off). Figure 2 shows the dependence of sensitivity and
specificity on the cut-off value for POD 4 and 7. Using the
cut-off value of 141 mg/L (95 % CI, 131–278 mg/L) for
POD 4 and after adjusting for the overall prevalence of
28.1 %, the positive predictive value (PPV) was 0.50 (95 %
CI, 0.37–0.63), and the negative predictive value (NPV) was
0.89 (95 % CI, 0.77–0.95). When adjusting for the 25.0 %
prevalence of PIC in patients with gastric cancer, the PPVwas
0.46 and the NPV was 0.91 in contrast to a PPVof 0.60 and a
NPVof 0.85 when adjusting for the 36.2 % prevalence of PIC
in patients with esophageal cancer. In multivariate ROC anal-
ysis, the diagnostic accuracy of CRP based on the area under
the ROC curve was not influenced by tumor site, neoadjuvant
therapy, or SDD (p>0.05 for POD 2 to POD 10).
Meta-analysis
Three studies could be identified by a literature search for
diagnostic accuracy of CRP after gastroesophageal cancer
surgery [10–12]. One study had to be excluded since no
diagnostic outcome data were provided [12]. The quality of
reporting of the remaining two studies was not optimal; espe-
cially the number of true/false negative and positive patients
was not provided. Deitmar et al. retrospectively assessed 558
patients with esophageal cancer who underwent an Ivor–Lew-
is esophagectomy. Anastomotic leakages occurred in 50
patients (8.9 %). The CRP levels in these 50 patients were
compared to 50 randomly chosen patients without this com-
plication [10]. Dutta et al. retrospectively analyzed the CRP
levels in 136 patients who had undergone esophagogastric
cancer resection (about half with gastric cancer). Fifty-four
(40 %) patients developed PIC and 17 patients (12.5 %)
developed an anastomotic leakage [11]. A meta-analysis for
sensitivity and specificity was performed pooling the data
from the studies mentioned above (Table 5) and our data
(Fig. 3). The highest sensitivity was found on POD 6 (0.72;
95 % CI, 0.59–0.85), and the highest specificity occurred on Ta
b
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POD 7 (0.88; 95 % CI, 0.81–0.94). Cochran's Q statistic
indicated considerable statistical heterogeneity for sensitivity
and specificity on PODs 2, 3, and 4 (p<0.001). Finally, a
meta-analysis using the diagnostic odds ratio was performed
(Fig. 4). Except for POD 2 (95 % CI includes 1), the diagnos-
tic value of CRP was statistically significant.
Discussion
This study identified the CRP level as a low to moderately
performing marker for PIC from PODs 4 to 7. CRP levels
before POD 4 did not have a relevant diagnostic value. A
meta-analysis including two further studies confirmed CRP
levels as a marker for PIC on POD 4. POD 4 is the best time
point for CRP measurement to monitor the postoperative
course after gastroesophageal cancer resection.
The observed morbidity and mortality in the present
study is comparable with those in other reports [3, 23].
Despite conflicting reports about its efficacy, we observed
a significantly decreased rate of septic complications after
enteral decontamination but no change in the diagnostic
accuracy of CRP [1, 14, 23]. The length of hospital stay
(LOS) in our study was longer than in other reports, prob-
ably due to the reimbursement policy in Switzerland favor-
ing long hospital stays. Nevertheless, the overall prolonged
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Table 5 Data extracted for meta-analysis
Study POD Data extraction AUC Cut-off [mg/L] nPIC nNo PIC Sensitivity Specificity
Deitmar et al. 2009 [10] 2 Graphically 0.56 135 50 50 0.92 0.20
3 Graphically 0.59 135 50 50 0.92 0.26
4 Graphically 0.66 135 50 50 0.86 0.46
5 Graphically 0.74 135 50 50 0.78 0.70
6 Graphically 0.81 135 50 50 0.76 0.86
7 Graphically 0.77 135 50 50 0.68 0.86
Dutta et al. 2011 [11] 3 Table 0.58 180 54 A) 69 0.52 0.64
4 Table 0.66 180 54 A) 69 0.43 0.90
a Thirteen patients with noninfectious complications excluded
PIC postoperative inflammatory complications
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LOS may be considered advantageous because the detection
rate for PIC may be higher.
The present study and meta-analysis identified CRP levels
on POD 4 as the earliest time for a relevant diagnostic accu-
racy. Although a higher diagnostic accuracy was found at later
time points, the early detection of PIC on POD 4 is clinically
important for the initiation of an early goal directed therapy to
improve the patients' outcomes [2, 5–8]. Furthermore, the
higher diagnostic accuracy after POD 4 in the present study
and the meta-analysis must be interpreted as caused by already
present PIC rather than their prediction. This hypothesis is
supported by Deitmar et al. [10] who demonstrated that ele-
vated CRP levels precede anastomotic leakage after gastro-
esophageal surgery by 3 days. When accounting for the
median occurrence of leaks at POD 7 in the present study,
the diagnostic value of CRP on POD 4 is well explained. As a
consequence and when accounting for the clinical context,
CRP measurements should be undertaken at POD 4 for a
detection of impendent complications. Elevated CRP levels
on this day should be followed by further diagnostic measures
like thoracic X-rays, upper gastrointestinal series, or CTscans.
In case of a positive finding an early goal-directed therapy of
potentially septic patients can performed, ultimately improv-
ing the patients' survival [5–8].
CRP is clearly not an optimal marker in particular since it is
difficult to distinguish between patients with PIC and patients
with a normal acute systemic inflammatory response caused
by the operation trauma. The normal acute inflammatory
response after surgery causes elevated CRP levels peaking
on POD 2 followed by a decrease with a half-life of 19 h [24]
as we observed in the control cohort without inflammatory
complications. Furthermore, CRP levels vary considerably
among patients without inflammatory complications. Thus,
the optimal time point of measuring CRP is very important.
Still, the diagnostic value of CRP levels was moderate at best.
Besides the optimal time for CRP measurement, the
correct choice of the threshold is also of great importance.
Our cut-off of 141 mg/L CRP on POD 4 corresponds well
with the cut-off of Deitmar et al. (135 mg/L) [10]. Dutta et
al. [11] reported a considerably higher value of 180 mg/L.
All reported cut-off values were in the same range and
additionally quite similar to the one (145 mg/L) reported
POD 2
Deitmar 2009
This study
Se: 0.51 [0.00−1.00]    Sp: 0.57 [0.00−1.00]
POD 3
Deitmar 2009
Dutta 2011
This study
Se: 0.71 [0.43−0.99]    Sp: 0.52 [0.26−0.78]
POD 4
Deitmar 2009
Dutta 2011
This study
Se: 0.69 [0.40−0.98]    Sp: 0.69 [0.41−0.97]
POD 5
Deitmar 2009
This study
Se: 0.71 [0.53−0.89]    Sp: 0.71 [0.62−0.81]
POD 6
Deitmar 2009
This study
Se: 0.72 [0.59−0.85]    Sp: 0.85 [0.77−0.92]
POD 7
Deitmar 2009
This study
Se: 0.64 [0.53−0.75]    Sp: 0.88 [0.81−0.94]
46/50
1/11
46/50
28/54
13/19
43/50
23/54
14/18
39/50
10/17
38/50
11/18
34/50
14/25
Sensitivity (TPR)
40/50
2/31
37/50
25/69
13/38
27/50
7/69
10/33
15/50
9/34
7/50
7/40
7/50
5/46
Specificity (1−FPR)
0 0.2 0.4 0.6 0.8 1 1 0.8 0.6 0.4 0.2 0
TPR FPRSTUDY
Fig. 3 Forest plot of the sensitivity and specificity of CRP levels from
PODs 2 to 7. TPR true positive rate (0sensitivity), FPR false positive
rate (01−specificity). Please note inverse scale of the right plot. Se
sensitivity, Sp specificity of the pooled data with 95 % confidence
interval in brackets based on a random effects model
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in a recent study about CRP levels after colorectal cancer
resection [25]. However, as a result of heterogeneity, low
sample size, and low diagnostic accuracy in our study, the
confidence intervals of our cut-off values were rather large
(131–278 mg/L on POD 4), thus our cut-off values can
therefore not be transferred to clinical routine.
Since the selection of the cut-off value has a strong influence
on sensitivity and specificity, it is difficult to compare these two
values in a meta-analysis. We thus also used the diagnostic
odds ratio for a meta-analysis, which is less influenced by the
choice of the threshold [22]. All studies used for the meta-
analysis chose the threshold by statistical optimization proce-
dures. This approach is a compromise usually resulting in
comparable sensitivity and specificity values. However, the
cut-off value can also be chosen by the clinical demands.
The uncertainty of the correct cut-off value simply reflects
the low to moderate diagnostic value of CRP levels. There-
fore, CRP cannot be used as a “black-and-white” decision
criterion that performs sufficiently well to correctly predict
PIC in clinical practice. Interpretation of CRP levels must be
considered in the context of the whole clinical picture. If in
doubt, further diagnostic measures should be added to the
clinical examination. Since the prevalence of PIC is higher
after esophageal than after gastric cancer resection, elevated
CRP levels have to be interpreted accordingly. The postoper-
ative decision-making process in patients with elevated CRP
levels must account for a higher likelihood of PIC after resec-
tion of esophageal cancer compared to gastric cancer.
In the last two decades, other acute phase proteins, par-
ticularly procalcitonin (PCT), were extensively investigated
as markers for systemic infections [26]. One study of 40
patients after esophageal cancer resection reported PCT as a
nearly perfect marker for postoperative infectious complica-
tions (AUCs of 0.97) [27]. Another study reported a signif-
icantly higher diagnostic value of PCT compared to CRP
(AUCs of 0.82 versus 0.68) after cardiac surgery [28].
However, in contrast to initially encouraging results, a recent
meta-analysis revealed only a low to moderate diagnostic value
of PCT to discriminate patients with sepsis from patients with
systemic inflammatory response syndrome [29]. Therefore, it is
still questionable that PCT performs much better than CRP in
the prediction of PIC. Recently, promising diagnostic values for
the cytokine interleukin 6 to predict of PIC after gastric cancer
resection and other major operations were reported [30, 31].
Our study has certain limitations. Although morbidity and
mortality rates after esophageal and gastric cancer resection
differ significantly [2–4], we pooled patients receiving either
of these treatments. This poolingmay have biased the diagnostic
1 10 20 30 40
Diagnostic odds ratio (DOR)
POD 2
Deitmar 2009 2.88 [1.00−9.88]
This study 1.45 [1.00−17.77]
pooled DOR 2.52 [1.00−7.61]
POD 3
Deitmar 2009 4.04 [1.22−13.43]
Dutta 2011 1.90 [1.00−3.91]
This study 4.17 [1.28−13.52]
pooled DOR 2.64 [1.52−4.56]
POD 4
Deitmar 2009 5.23 [1.98−13.85]
Dutta 2011 6.57 [2.54−16.98]
This study 8.05 [2.12−30.63]
pooled DOR 6.27 [3.42−11.50]
POD 5
Deitmar 2009 8.27 [3.36−20.39]
This study 3.97 [1.16−13.58]
pooled DOR 6.40 [3.09−13.24]
POD 6
Deitmar 2009 19.45 [6.95−54.45]
This study 7.41 [2.12−25.86]
pooled DOR 12.85 [5.04−32.78]
POD 7
Deitmar 2009 13.05 [4.82−35.33]
This study 10.44 [3.08−35.31]
pooled DOR 11.94 [5.52−25.81]
Fig. 4 Forest plot of diagnostic odds ratios for CRP from PODs 2 to 7.
Diagnostic odds ratios (DOR) for CRP from PODs 2 to 7 with pooled
(random effects) estimates. Squares represent individual studies and
are provided with 95 % Cis. Diamonds represent the pooled diagnostic
odds ratio. The size of the squares is proportional to the weight of the
study
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values beside a heterogeneous patient cohort with low case
numbers, even though multivariate ROC analysis did not indi-
cate such a bias. Data were retrieved from a single center cohort
over a rather long time of more than 10 years. Hence, incom-
plete or biased documentation particularly of the earlier cases
cannot be excluded which would result in an underestimation
of the inflammatory complications. Except for anastomotic
leakage, the time point of initial diagnosis of inflammatory
complications was not assessed. We cannot exclude the possi-
bility of other forms of bias affecting the selection of patients or
the diagnostic performance of CRP. In addition, the meta-
analysis suffered from low sample size, low quality of report-
ing, and considerable clinical and statistical heterogeneity most
likely due to the rather differing proportion of patients with
gastric cancer in these studies (0–72 %).
Conclusion
CRP levels on POD 4 have a low to moderate diagnostic
performance to predict inflammatory complications. Elevated
CRP levels on POD 4 can also be caused by the normal
postoperative inflammatory response, thus the interpretation
of the CRP levels must be seen in the context of the entire
clinical situation.
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